No PR and an AdCom is a potential scenario that could cause a short term drop. I would think. Although as others have pointed out, this stock seems to trade opposite of what we expect :)
No price pop with priority review and Ad Com. Price will react to aftermath of Ad Com and that's the advantage of knowing when to place the straddle position. If July Ad Com...VERY likely this was leaked.
Any manipulation that keeps the price lower does irreparable damages...
If Europe news comes prior to cheaters taking advantage of July options; stock will be held down for them to exit position...
Time will tell, but this is WHY the FDA should have communicated speed of review prior to trusting their Swiss cheese system of leaks and bad regulation.